Do analysts prefer STRO or DTSQ?

Sutro Biopharma presently has a consensus price target of $52.00, suggesting a potential upside of 103.23%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Sutro Biopharma is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sutro Biopharma 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.92 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, STRO or DTSQ?

DT Cloud Star Acquisition has lower revenue, but higher earnings than Sutro Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sutro Biopharma $102.48M 4.14 -$191.09M -$11.04 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is STRO or DTSQ more profitable?

DT Cloud Star Acquisition has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Company Net Margins Return on Equity Return on Assets Sutro Biopharma -154.21% N/A -69.20% DT Cloud Star Acquisition N/A N/A N/A

Do analysts prefer DTSQ or XFOR?

X4 Pharmaceuticals has a consensus price target of $9.70, indicating a potential upside of 116.76%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 X4 Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has better valuation and earnings, DTSQ or XFOR?

DT Cloud Star Acquisition has higher earnings, but lower revenue than X4 Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A X4 Pharmaceuticals $35.11M 12.02 -$79.20M -$1.20 N/A

Does the media refer more to DTSQ or XFOR?

In the previous week, X4 Pharmaceuticals had 7 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 9 mentions for X4 Pharmaceuticals and 2 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 0.69 beat X4 Pharmaceuticals' score of 0.49 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DT Cloud Star Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer ABEO or DTSQ?

Abeona Therapeutics currently has a consensus target price of $19.00, indicating a potential upside of 166.29%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, ABEO or DTSQ?

Abeona Therapeutics has higher revenue and earnings than DT Cloud Star Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abeona Therapeutics $5.82M 69.87 $71.18M $0.97 7.36 DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is ABEO or DTSQ more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -53.98% -38.52% DT Cloud Star Acquisition N/A N/A N/A

Does the media prefer ABEO or DTSQ?

In the previous week, Abeona Therapeutics had 2 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Abeona Therapeutics and 2 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 0.69 beat Abeona Therapeutics' score of 0.00 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DT Cloud Star Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate DTSQ or RCKT?

Rocket Pharmaceuticals has a consensus target price of $8.71, suggesting a potential upside of 141.73%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rocket Pharmaceuticals 3 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.30

Which has preferable earnings and valuation, DTSQ or RCKT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$1.87 N/A

Is DTSQ or RCKT more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets DT Cloud Star Acquisition N/A N/A N/A Rocket Pharmaceuticals N/A -69.61% -58.63%

Does the media favor DTSQ or RCKT?

In the previous week, DT Cloud Star Acquisition and DT Cloud Star Acquisition both had 2 articles in the media. DT Cloud Star Acquisition's average media sentiment score of 0.69 beat Rocket Pharmaceuticals' score of 0.34 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DT Cloud Star Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DTSQ or UPB?

Upstream Bio has a consensus price target of $33.17, indicating a potential upside of 342.87%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts plainly believe Upstream Bio is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Upstream Bio 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has stronger valuation & earnings, DTSQ or UPB?

DT Cloud Star Acquisition has higher earnings, but lower revenue than Upstream Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Upstream Bio $3.32M 122.68 -$143.44M -$2.91 N/A

Does the media refer more to DTSQ or UPB?

In the previous week, DT Cloud Star Acquisition and DT Cloud Star Acquisition both had 2 articles in the media. DT Cloud Star Acquisition's average media sentiment score of 0.69 beat Upstream Bio's score of 0.60 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DT Cloud Star Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DT Cloud Star Acquisition (DTSQ) Competitors

$11.32 +0.08 (+0.71%)

As of 10:43 AM Eastern

Compare

DTSQ vs. STRO, XFOR, ABEO, RCKT, and UPB

Should you buy DT Cloud Star Acquisition stock or one of its competitors? MarketBeat compares DT Cloud Star Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DT Cloud Star Acquisition include Sutro Biopharma (STRO), X4 Pharmaceuticals (XFOR), Abeona Therapeutics (ABEO), Rocket Pharmaceuticals (RCKT), and Upstream Bio (UPB). These companies are all part of the "biotechnology" industry.

How does DT Cloud Star Acquisition compare to Sutro Biopharma?

Sutro Biopharma (NASDAQ:STRO) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Sutro Biopharma has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

DT Cloud Star Acquisition has lower revenue, but higher earnings than Sutro Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	4.14	-$191.09M	-$11.04	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

97.0% of Sutro Biopharma shares are held by institutional investors. 1.8% of Sutro Biopharma shares are held by insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

DT Cloud Star Acquisition has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
DT Cloud Star Acquisition	N/A	N/A	N/A

In the previous week, DT Cloud Star Acquisition had 2 more articles in the media than Sutro Biopharma. MarketBeat recorded 2 mentions for DT Cloud Star Acquisition and 0 mentions for Sutro Biopharma. DT Cloud Star Acquisition's average media sentiment score of 0.69 beat Sutro Biopharma's score of 0.00 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Sutro Biopharma	Neutral
DT Cloud Star Acquisition	Positive

Sutro Biopharma presently has a consensus price target of $52.00, suggesting a potential upside of 103.23%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Sutro Biopharma is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sutro Biopharma beats DT Cloud Star Acquisition on 7 of the 12 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to X4 Pharmaceuticals?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

DT Cloud Star Acquisition has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. DT Cloud Star Acquisition's return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
X4 Pharmaceuticals	-568.80%	-64.95%	-37.33%

DT Cloud Star Acquisition has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 52.9% of DT Cloud Star Acquisition shares are owned by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

X4 Pharmaceuticals has a consensus price target of $9.70, indicating a potential upside of 116.76%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

DT Cloud Star Acquisition has higher earnings, but lower revenue than X4 Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
X4 Pharmaceuticals	$35.11M	12.02	-$79.20M	-$1.20	N/A

In the previous week, X4 Pharmaceuticals had 7 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 9 mentions for X4 Pharmaceuticals and 2 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 0.69 beat X4 Pharmaceuticals' score of 0.49 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DT Cloud Star Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

X4 Pharmaceuticals beats DT Cloud Star Acquisition on 7 of the 12 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Abeona Therapeutics currently has a consensus target price of $19.00, indicating a potential upside of 166.29%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Abeona Therapeutics has higher revenue and earnings than DT Cloud Star Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	69.87	$71.18M	$0.97	7.36
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Abeona Therapeutics had 2 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Abeona Therapeutics and 2 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 0.69 beat Abeona Therapeutics' score of 0.00 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DT Cloud Star Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.6% of Abeona Therapeutics shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

DT Cloud Star Acquisition's return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
DT Cloud Star Acquisition	N/A	N/A	N/A

Abeona Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

Summary

Abeona Therapeutics beats DT Cloud Star Acquisition on 7 of the 11 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Rocket Pharmaceuticals?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

DT Cloud Star Acquisition has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

In the previous week, DT Cloud Star Acquisition and DT Cloud Star Acquisition both had 2 articles in the media. DT Cloud Star Acquisition's average media sentiment score of 0.69 beat Rocket Pharmaceuticals' score of 0.34 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DT Cloud Star Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rocket Pharmaceuticals has a consensus target price of $8.71, suggesting a potential upside of 141.73%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

DT Cloud Star Acquisition's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 52.9% of DT Cloud Star Acquisition shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Rocket Pharmaceuticals beats DT Cloud Star Acquisition on 6 of the 10 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Upstream Bio?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

DT Cloud Star Acquisition has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

DT Cloud Star Acquisition has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. DT Cloud Star Acquisition's return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Upstream Bio	-4,718.96%	-43.82%	-42.27%

In the previous week, DT Cloud Star Acquisition and DT Cloud Star Acquisition both had 2 articles in the media. DT Cloud Star Acquisition's average media sentiment score of 0.69 beat Upstream Bio's score of 0.60 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DT Cloud Star Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Upstream Bio has a consensus price target of $33.17, indicating a potential upside of 342.87%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts plainly believe Upstream Bio is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

DT Cloud Star Acquisition has higher earnings, but lower revenue than Upstream Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Upstream Bio	$3.32M	122.68	-$143.44M	-$2.91	N/A

Summary

Upstream Bio beats DT Cloud Star Acquisition on 5 of the 9 factors compared between the two stocks.

Get DT Cloud Star Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTSQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DTSQ vs. The Competition

Export

Metric	DT Cloud Star Acquisition	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$100.75M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	N/A	9.06	269.93	24.86
Price / Sales	N/A	1,267.27	650.62	108.28
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	N/A	17.63	11.25	6.44
Net Income	N/A	-$13.25M	$3.45B	$347.39M
7 Day Performance	-0.13%	5.49%	3.67%	2.69%
1 Month Performance	-0.26%	-1.66%	-0.49%	-0.90%
1 Year Performance	7.76%	61.27%	77.44%	23.51%

DT Cloud Star Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DTSQ DT Cloud Star Acquisition	1.315 of 5 stars	$11.32 +0.7%	N/A	+6.8%	$100.75M	N/A	N/A	N/A	Earnings Report
STRO Sutro Biopharma	2.6637 of 5 stars	$25.38 +5.1%	$52.00 +104.9%	+216.3%	$400.18M	$102.48M	N/A	240	Analyst Forecast
XFOR X4 Pharmaceuticals	2.4455 of 5 stars	$4.64 +11.3%	$9.70 +109.1%	+211.4%	$393.31M	$35.11M	N/A	80	News Coverage Earnings Report Analyst Revision High Trading Volume
ABEO Abeona Therapeutics	3.0189 of 5 stars	$7.24 +4.9%	$19.00 +162.4%	+15.7%	$393.27M	$5.82M	7.46	90	Upcoming Earnings
RCKT Rocket Pharmaceuticals	2.5649 of 5 stars	$3.61 +2.0%	$8.71 +141.4%	+26.2%	$386.55M	N/A	N/A	240	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DTSQ) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DT Cloud Star Acquisition (DTSQ) Competitors

DTSQ vs. STRO, XFOR, ABEO, RCKT, and UPB

How does DT Cloud Star Acquisition compare to Sutro Biopharma?

Summary

How does DT Cloud Star Acquisition compare to X4 Pharmaceuticals?

Summary

How does DT Cloud Star Acquisition compare to Abeona Therapeutics?

Summary

How does DT Cloud Star Acquisition compare to Rocket Pharmaceuticals?

Summary

How does DT Cloud Star Acquisition compare to Upstream Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTSQ vs. The Competition

DT Cloud Star Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DT Cloud Star Acquisition (DTSQ) Competitors

DTSQ vs. STRO, XFOR, ABEO, RCKT, and UPB

How does DT Cloud Star Acquisition compare to Sutro Biopharma?

Which has more volatility & risk, STRO or DTSQ?

Which has preferable valuation & earnings, STRO or DTSQ?

Do institutionals and insiders hold more shares of STRO or DTSQ?

Is STRO or DTSQ more profitable?

Does the media favor STRO or DTSQ?

Do analysts prefer STRO or DTSQ?

Summary

How does DT Cloud Star Acquisition compare to X4 Pharmaceuticals?

Is DTSQ or XFOR more profitable?

Which has more risk & volatility, DTSQ or XFOR?

Do insiders & institutionals believe in DTSQ or XFOR?

Do analysts prefer DTSQ or XFOR?

Which has better valuation and earnings, DTSQ or XFOR?

Does the media refer more to DTSQ or XFOR?

Summary

How does DT Cloud Star Acquisition compare to Abeona Therapeutics?

Do analysts prefer ABEO or DTSQ?

Which has preferable earnings & valuation, ABEO or DTSQ?

Does the media prefer ABEO or DTSQ?

Do institutionals and insiders believe in ABEO or DTSQ?

Is ABEO or DTSQ more profitable?

Which has more risk and volatility, ABEO or DTSQ?

Summary

How does DT Cloud Star Acquisition compare to Rocket Pharmaceuticals?

Which has more volatility & risk, DTSQ or RCKT?

Does the media favor DTSQ or RCKT?

Do analysts rate DTSQ or RCKT?

Which has preferable earnings and valuation, DTSQ or RCKT?

Is DTSQ or RCKT more profitable?

Do institutionals and insiders hold more shares of DTSQ or RCKT?

Summary

How does DT Cloud Star Acquisition compare to Upstream Bio?

Which has more risk & volatility, DTSQ or UPB?

Is DTSQ or UPB more profitable?

Does the media refer more to DTSQ or UPB?

Do analysts rate DTSQ or UPB?

Which has stronger valuation & earnings, DTSQ or UPB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTSQ vs. The Competition

DT Cloud Star Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools